What is William Blair's Estimate for LFST Q1 Earnings?

Key Points

• William Blair estimates that LifeStance Health Group will post $0.02 EPS for Q1 2026, with subsequent quarterly estimates ranging from $0.01 to $0.02 EPS.
• In its most recent earnings report, LifeStance Health Group exceeded expectations by reporting ($0.01 EPS) against a consensus estimate of ($0.03 EPS).
• The company saw a revenue increase of 10.6% compared to the same quarter last year, totaling $345.31 million.

LifeStance Health Group, Inc. (NASDAQ:LFST - Free Report) - Analysts at William Blair issued their Q1 2026 earnings per share (EPS) estimates for shares of LifeStance Health Group in a research note issued to investors on Thursday, August 7th. William Blair analyst R. Daniels forecasts that the company will post earnings per share of $0.02 for the quarter. The consensus estimate for LifeStance Health Group's current full-year earnings is ($0.18) per share. William Blair also issued estimates for LifeStance Health Group's Q2 2026 earnings at $0.01 EPS, Q3 2026 earnings at $0.02 EPS and Q4 2026 earnings at $0.02 EPS.

LifeStance Health Group (NASDAQ:LFST - Get Free Report) last issued its quarterly earnings data on Thursday, August 7th. The company reported ($0.01) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.03) by $0.02. LifeStance Health Group had a negative return on equity of 2.47% and a negative net margin of 2.78%. The firm had revenue of $345.31 million during the quarter, compared to the consensus estimate of $345.05 million. During the same quarter in the previous year, the company posted ($0.06) EPS. The business's revenue for the quarter was up 10.6% compared to the same quarter last year.

A number of other equities research analysts also recently weighed in on LFST. BTIG Research initiated coverage on LifeStance Health Group in a research report on Friday, July 25th. They set a "buy" rating and a $8.00 target price for the company. UBS Group upgraded LifeStance Health Group from a "neutral" rating to a "buy" rating and set a $8.50 target price for the company in a research report on Tuesday, May 27th. One equities research analyst has rated the stock with a sell rating, five have issued a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat, the company has an average rating of "Moderate Buy" and an average target price of $8.42.

LifeStance Health Group Price Performance

LFST traded up $0.26 during trading on Friday, hitting $4.12. The company's stock had a trading volume of 1,531,998 shares, compared to its average volume of 1,870,973. The firm's 50 day moving average price is $4.80 and its two-hundred day moving average price is $6.22. The company has a quick ratio of 1.47, a current ratio of 1.47 and a debt-to-equity ratio of 0.19. LifeStance Health Group has a 12 month low of $3.74 and a 12 month high of $8.61. The stock has a market capitalization of $1.60 billion, a price-to-earnings ratio of -41.35 and a beta of 1.13.

Institutional Investors Weigh In On LifeStance Health Group

Institutional investors have recently made changes to their positions in the stock. Parcion Private Wealth LLC acquired a new position in LifeStance Health Group in the first quarter valued at about $15,670,000. Dimensional Fund Advisors LP grew its stake in LifeStance Health Group by 87.4% in the fourth quarter. Dimensional Fund Advisors LP now owns 3,524,529 shares of the company's stock valued at $25,977,000 after acquiring an additional 1,643,390 shares during the period. Jacobs Levy Equity Management Inc. acquired a new position in LifeStance Health Group in the first quarter valued at about $7,932,000. Nuveen LLC acquired a new position in LifeStance Health Group in the first quarter valued at about $6,928,000. Finally, Vanguard Group Inc. grew its stake in LifeStance Health Group by 7.9% in the fourth quarter. Vanguard Group Inc. now owns 10,689,396 shares of the company's stock valued at $78,781,000 after acquiring an additional 784,818 shares during the period. 85.50% of the stock is owned by institutional investors and hedge funds.

Insider Activity at LifeStance Health Group

In related news, insider Ujjwal Ramtekkar sold 16,000 shares of LifeStance Health Group stock in a transaction on Thursday, June 5th. The stock was sold at an average price of $5.94, for a total transaction of $95,040.00. Following the completion of the sale, the insider directly owned 113,435 shares of the company's stock, valued at $673,803.90. The trade was a 12.36% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 3.20% of the stock is currently owned by company insiders.

About LifeStance Health Group

LifeStance Health Group, Inc, through its subsidiaries, provides outpatient mental health services to children, adolescents, adults, and geriatrics in the United States. The company offers patients a suite of mental health services, including psychiatric evaluations and treatment, psychological, and neuropsychological testing, as well as individual, family, and group therapy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.